Adlai Nortye Ltd American Depositary Shares ANL

$1.50 +0.03 (2.04%)

Valuation

Market cap
57,199,000
Revenue TTM
$0
Net income TTM
$-51,870,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
1.03

Trading

Volume
846
Avg volume
19,594
Day's range
$1.48 – $1.52
Shares out
36,900,000
Stochastic %K
21%
Beta
-0.83
Analysts
Hold
Price target
$9.00

Price

Company profile

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibi...

Show more

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in North Brunswick, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Phone
848 230 7430
Website
https://www.adlainortye.com
Address
77 Robinson Road, 2nd floor #20-01, Singapore, Singapore

Latest news

Stocktwits

focafoca99 Sep 30, 10:12 AM
$ANL has held an extraordinary shareholders meeting where all resolutions were approved.
0 replies
SqueezeSpecs Sep 27, 11:37 AM
$ANL: Adlai Nortye announced that the first patient has been dosed in Australia and the U.S. FDA has cleared its IND for AN4035, a pan-RAS(ON) inhibitor-based antibody-drug conjugate. The company is now advancing the program into clinical development for RAS-driven cancers. ANL closed September 25 at $15.53, down 1.90%. The stock remains well above its 52-week low of $0.88 and below its 52-week high of $17.25.
0 replies
notreload_ai Sep 10, 2:03 PM
$ANL $FATN $FDXF $INTC $CLOV -- THE WSJ
0 replies
prismmarketview Sep 8, 2:52 PM
$ANL Adlai Nortye announced first-patient dosing in Australia for its global Phase 1 trial of AN4035, alongside a U.S. FDA “Study May Proceed” letter allowing the trial to expand into the U.S. AN4035 is an investigational CEACAM5-targeting, pan-RAS(ON) inhibitor-based ADC for RAS-addicted solid tumors. https://prismmarketview.com/adlai-nortye-begins-global-phase-1-trial-of-an4035-after-u-s-fda-ind-clearance/
0 replies
IntiTheSunGod Sep 5, 7:09 PM
$ANL BNY Mellon is a major shareholder of ANL. ANL ytd is up over 900% ANL is an Aussie pharmaceutical company. BNY also retains 44% of $IMMURON Ltd shares and IMRN is up 136% ytd. Yesterday IMRN daily volume was over 120M vs an avg of 230k
0 replies
Stonkykong67 Aug 24, 2:34 PM
Can’t pick a stock for shite so I’m just gonna throw out a flyer $ANL
1 replies
Doozio Aug 19, 12:40 AM
$ANL and? Prolly right this ⏰? 🧠⏰?
0 replies
ProbablyWrongAgain Aug 4, 5:13 AM
$ANL interested, starting to do dd
0 replies